Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
2023 · New England Journal of Medicine · 220 citations
https://doi.org/10.1056/nejmoa2210140
S
Shivaani Kummar
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
645
Papers
14.9K
Citations
58
h-index
179
i10-index
Shivaani Kummar is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & PARP inhibition in cancer therapy. The author has an h-index of 58, co-authored 549 publications.
ORCID: 0000-0001-6906-1627Papers by this author
worksClinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)
2017 · Journal of Clinical Oncology · 187 citations
https://doi.org/10.1200/jco.2016.71.1994
Advances in using PARP inhibitors to treat cancer
2012 · BMC Medicine · 152 citations
https://doi.org/10.1186/1741-7015-10-25
Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells
2016 · Seminars in Oncology · 132 citations
https://doi.org/10.1053/j.seminoncol.2016.06.004
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
2012 · Clinical Cancer Research · 129 citations
https://doi.org/10.1158/1078-0432.ccr-11-2484
Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma
2002 · British Journal of Cancer · 114 citations
https://doi.org/10.1038/sj.bjc.6600326
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat